Medical oncology
Radiation oncology
breast cancer could safely omit radiation therapy following breast-conserving surgery and endocrine treatment. The trial enrolled 1,176 participants overall, with GenesisCare contributing an impressive 12% patients across multiple sites. The study closely aligns with our focus on personalised, evidence-based care. Many participants reported valuing the opportunity to contribute to research that may shape future treatment pathways, as well as the reassurance provided by close clinical follow-up throughout the trial. Radiation oncologist Dr Esther Sim, one of the study’s Principal Investigators, shared her perspective:
One exciting area in cancer treatment is antibody drug conjugates (ADCs). These are targeted therapies that combine monoclonal antibodies with powerful anticancer drugs. They’re designed to deliver treatment directly to cancer cells that express specific antigens— like HER2—while limiting damage to healthy cells. Because of their potential, ADCs have become a fast-growing area of research, with many new therapies being developed and approved over the past decade. One of these studies is the Dynasty 02 trial, a phase III clinical study for people with HER2 low, hormone receptor–positive metastatic breast cancer. Participants are randomly assigned either to the investigational ADC or to one of several standard chemotherapy options, including capecitabine, paclitaxel, or nabpaclitaxel. Study Investigator and medical oncologist Dr Nick Murray shares his thoughts on the trial:
GenesisCare’s clinical research team is currently running 21 active radiation oncology trials, reflecting our strong and ongoing commitment to advancing cancer care. Radiation therapy remains a major focus because these studies are critical to identifying safer and more effective treatments, improving survival and quality-of-life, and driving innovation in technology and care delivery. With one of the most extensive radiation oncology networks spanning metropolitan and regional locations, GenesisCare is committed to making clinical trials accessible to patients regardless of where they live. A strong example of this commitment is our involvement in the Breast Cancer Trials EXPERT trial. This phase III study investigated whether women with low-risk, early-stage luminal A
With over 93 active medical oncology trials, it is evident our GenesisCare Research and Leadership teams are dedicated to providing quality clinical research to the Australian community. Breast cancer remains an important area of research. It was the second most commonly diagnosed cancer in Australia in 2021 and is expected to stay in that position for a number of years. In 2021, more than 19,000 Australians were diagnosed with breast cancer, and that number is estimated to rise to just over 20,000 in 2025. 10 Medical oncologist Dr Nick Murray specialises in breast cancer and believes strongly in giving patients access to new treatments through clinical trials. Based at GenesisCare in Adelaide, he leads several trials as a Principal Investigator.
We have valued the opportunity to be one of the highest-enrolling contributors to this important research, which aims to improve treatment outcomes for women with early breast cancer. Personalising radiation treatment allows us to enhance quality-of-life by reducing long-term toxicities while preserving treatment effectiveness.
This trial offers an important opportunity for patients whose
cancer has progressed after standard treatments. It provides access to a therapy that isn’t otherwise available. If the investigational ADC proves to be more effective or easier to tolerate than current chemotherapy options, it could lead to better outcomes for future patients.
93
12 Research projects /registries
14 Research sites 4 Publications and presentations
21
11 Research projects /registries
55
20
41
Clinical trials
Investigators
Clinical trials
Publications and presentaions
Investigators
43
65
16
724
Top disease sites Prostate, Breast, Basket
Prostate, Lung, Breast Top disease sites
3262
External sponsors
Research sites
Patients in trials
External sponsors
Patients in trials
18
19
Made with FlippingBook Annual report maker